
|Articles|April 1, 2003
Efalizumab Efficiency
San Francisco -- Results from Phase III clinical trials support the efficacy and safety of efalizumab (Raptiva), the humanized CD-11a monoclonal antibody, as a chronic treatment for moderate-to-severe plaque psoriasis, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Hilary Baldwin, MD, Highlights Emerging Acne and Rosacea Therapies at Elevate-Derm
2
Triamcinolone Shows Transcriptomic Shifts in AD Within 24 Hours
3
Douglas DiRuggiero, PA-C, DMSc, Recognized at the Elevate-Derm Fall Conference
4
Education and Engagement Drive Momentum in Hair Disorders
5



















